TITLE

Clinical trial for Fabry disease faces continuing hurdles

AUTHOR(S)
Silversides, Ann
PUB. DATE
November 2009
SOURCE
CMAJ: Canadian Medical Association Journal;11/24/2009, Vol. 181 Issue 11, pE251
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article informs that the clinical trial for Fabry disease conducted by the Canadian Fabry Disease Initiative is facing problems because of the worldwide shortage of one of the enzyme replacement therapies. It is stated that the trial involves a comparison of the agalsidase beta (Fabrazyme) and agasidase alfa (Replegal), but the global shortage of agalsidase beta has created new challenges like reducing dose of Fabrazyme to patients and threatening the integrity of the post market trial.
ACCESSION #
45520301

 

Related Articles

  • Observational Data Under the Microscope. Kubick, Wayne R. // Applied Clinical Trials;Apr2009, Vol. 18 Issue 4, p34 

    The article discusses the importance of using longitudinal health care data in clinical research in the U.S. It says that the data can be used in providing early warnings and assessment of potential safety issues, exploring and verifying safety signals of the patients, and for better...

  • RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Curtis, J. R.; Westfall, A. O.; Cheng, H.; Saag, K. G.; Delzell, E. // Osteoporosis International;Jun2009, Vol. 20 Issue 6, p973 

    The comparative effectiveness of alendronate and risedronate has received limited evaluation. Among 19,063 new users of bisphosphonates, risedronate users had a higher relative rate of hip fracture compared to alendronate users, but the difference in absolute fracture rate was small. We conclude...

  • Patients' Attitudes and Preferences About Participation and Recruitment Strategies in Clinical Trials. Sood, Amit; Prasad, Kavita; Chhatwani, Laveena; Shinozaki, Eri; Cha, Stephen S.; Loehrer, Laura L.; Wahner-Roedler, Dieteind L. // Mayo Clinic Proceedings;Mar2009, Vol. 84 Issue 3, p243 

    OBJECTIVE: To assess attitudes of patients about participation in clinical trials. PATIENTS AND METHODS: This is a self-report survey of 400 patients who underwent general medical evaluations between September and November 2006 at a tertiary care academic medical center in Rochester, MN. We...

  • The Tinnitus Research Initiative (TRI) database: A new approach for delineation of tinnitus subtypes and generation of predictors for treatment outcome. Landgrebe, Michael; Zeman, Florian; Koller, Michael; Eberl, Yvonne; Mohr, Markus; Reiter, Jean; Staudinger, Susanne; Hajak, Goeran; Langguth, Berthold // BMC Medical Informatics & Decision Making;2010, Vol. 10 Issue 1, p42 

    Tinnitus, the phantom perception of sound, is a frequent disorder that causes significant morbidity and treatment is elusive. A large variety of different treatment options have been proposed and from most of them some patients benefit. However, a particular treatment that helps one patient may...

  • Methods of Blinding in Reports of Randomized Controlled Trials Assessing Pharmacologic Treatments: A Systematic Review. Boutron, Isabelle; Estellat, Candice; Guittet, Lydia; Dechartres, Agnes; Sackett, David L.; Hróbjartsson, Asbjørn; Ravaud, Philippe // PLoS Medicine;Oct2006, Vol. 3 Issue 10, p1931 

    Background Blinding is a cornerstone of therapeutic evaluation because lack of blinding can bias treatment effect estimates. An inventory of the blinding methods would help trialists conduct high-quality clinical trials and readers appraise the quality of results of published trials. We aimed to...

  • Clinical Trials and Medical Care: Defining the Therapeutic Misconception. Henderson, Gail E.; Churchill, Larry R.; Davis, Arlene M.; Easter, Michele M.; Grady, Christine; Joffe, Steven; Kass, Nancy; King, Nancy M. P.; Lidz, Charles W.; Miller, Franklin G.; Nelson, Daniel K.; Peppercorn, Jeffrey; Rothschild, Barbra Bluestone; Sankar, Pamela; Wilfond, Benjamin S.; Zimmer, Catherine R. // PLoS Medicine;Nov2007, Vol. 4 Issue 11, pe324 

    A key component of informed consent to participate in medical research includes understanding that research is not the same as treatment.

  • Challenges in Using Nonrandomized Studies in Systematic Reviews of Treatment Interventions. Norris, Susan L.; Atkins, David // Annals of Internal Medicine;6/21/2005 Supplement, Vol. 142, p1112 

    Randomized, controlled trials (RCTs) are firmly established as the standard for determining which medical treatments are effective. In some areas of health care, however, among them surgery, public health, and the organization of health care delivery, most evidence addressing the effectiveness...

  • Promising results for new tuberculosis therapy. Bagchi, Sanjit // CMAJ: Canadian Medical Association Journal;1/1/2008, Vol. 178 Issue 1, p19 

    The article talks about the possibility of having a shorter duration treatment for tuberculosis as shown in preliminary findings from a clinical trial. The findings show that new combination therapy which includes Moxifloxacin, an antibiotic, has the capability to cut the needed time to sure...

  • MENA: The Dawn of a New Era. Abraham, Rani // Applied Clinical Trials;Apr2011, Vol. 20 Issue 4, p36 

    The article reports on the clinical research increase in Middle East and North Africa in 2011. It notes that there has been significant increase of investment in healthcare and modern hospitals incorporating state of the art equipment for organizing clinical trials in the regions. It notes that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics